NR3C2 and heart failure: Importantly, use of guideline-based heart failure therapy including ACE-inhibitors or angiotensin receptor blocker (ARB), beta-blockade and mineralocorticoid receptor antagonist (MRA) [11] during the study was high and did not differ between both groups (Suppl.